4.5 Article

Evaluating Alzheimer's disease biomarkers as mediators of age-related cognitive decline

期刊

NEUROBIOLOGY OF AGING
卷 58, 期 -, 页码 120-128

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2017.06.022

关键词

CSF biomarkers; Structural imaging; MRI; Cognition; Longitudinal modeling; Parallel process model

资金

  1. National Institute on Aging [R13 AG030995, P30 AG10129, R01 AG031563, R01 AG047827, R01 AG051170, P30 AG043097]
  2. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  3. DOD ADNI (Department of Defense award) [W81XWH-12-2-0012]
  4. National Institute on Aging
  5. National Institute of Biomedical Imaging and Bioengineering
  6. AbbVie
  7. Alzheimer's Association
  8. Alzheimer's Drug Discovery Foundation
  9. Araclon Biotech
  10. Bio-Clinica, Inc
  11. Biogen
  12. Bristol-Myers Squibb Company
  13. CereSpir, Inc
  14. Cogstate
  15. Eisai Inc
  16. Elan Pharmaceuticals, Inc
  17. Eli Lilly and Company
  18. EUROIMMUN
  19. F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc
  20. Fujirebio
  21. GE Healthcare
  22. IXICO Ltd
  23. Janssen Alzheimer Immunotherapy Research & Development, LLC
  24. Johnson & Johnson Pharmaceutical Research & Development LLC
  25. Lumosity
  26. Lundbeck
  27. Merck Co, Inc
  28. Meso Scale Diagnostics, LLC
  29. NeuroRx Research
  30. Neurotrack Technologies
  31. Novartis Pharmaceuticals Corporation
  32. Pfizer Inc
  33. Piramal Imaging
  34. Servier
  35. Takeda Pharmaceutical Company
  36. Transition Therapeutics
  37. Canadian Institutes of Health Research

向作者/读者索取更多资源

Age-related changes in cognition are partially mediated by the presence of neuropathology and neurodegeneration. This manuscript evaluates the degree to which biomarkers of Alzheimer's disease, (AD) neuropathology and longitudinal changes in brain structure, account for age-related differences in cognition. Data from the AD Neuroimaging Initiative (n = 1012) were analyzed, including individuals with normal cognition and mild cognitive impairment. Parallel process mixed effects regression models characterized longitudinal trajectories of cognitive variables and time-varying changes in brain volumes. Baseline age was associated with both memory and executive function at baseline (p's < 0.001) and change in memory and executive function performances over time (p's < 0.05). After adjusting for clinical diagnosis, baseline, and longitudinal changes in brain volume, and baseline levels of cerebrospinal fluid biomarkers, age effects on change in episodic memory and executive function were fully attenuated, age effects on baseline memory were substantially attenuated, but an association remained between age and baseline executive function. Results support previous studies that show that age effects on cognitive decline are fully mediated by disease and neurodegeneration variables but also show domain-specific age effects on baseline cognition, specifically an age pathway to executive function that is independent of brain and disease pathways. (C) 2017 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据